The following players span a variety of industries, so if you pick up more than one, you may gain in diversification.

Crispr Therapeutics AG ( ($CRSP) ) has risen by 9.03%. Read on to learn why. Crispr Therapeutics AG has seen its stock price rise by 9.03% over ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this involves a beaten-down biotech stock that Wood has been buying regularly ...

Discover why Crispr Therapeutics AG is a strong buy with FDA-approved Casgevy, a promising pipeline, and major growth ...

India's GenAI infrastructure is being built, but can a public-private partnership outpace the trillion-dollar budgets of US ...

CRISPR Therapeutics AG (NASDAQ:CRSP) ranks among the best short squeeze stocks to buy right now. Citizens reaffirmed its Market Outperform rating and $86 price target for CRISPR Therapeutics AG ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $500.0 and $750.0 for Regeneron Pharmaceuticals, spanning the ...

Discover top biotech companies for 2026, featuring emerging stars and leaders set for major clinical and regulatory ...

Tenaya Therapeutics remains pre-revenues, and it’s a thinly traded microcap. Its tight cash runway is also a concern. Read ...

Healthcare stocks as a group have not performed on par with broader equities this year. However, that doesn't mean investors ...

Although existing CRISPR-Cas-based imaging methods can target endogenous genomic sequences, their applications are limited by system complexity and sensitivity, particularly when imaging ...

A major medical milestone took place in May 2025, when doctors at the Children’s Hospital of Philadelphia used CRISPR-based gene editing to treat a child with a rare genetic disorder. Unlike earlier ...